Drug Trial Radar · NCT07792928
A Study of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Adults
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Oct 14, 2026
Primary completion
Nov 10, 2026
Study completion Nov 10, 2026
Sponsor
- Lead sponsor
- Shanghai Peptidstar Therapeutics LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Emerald Clinical Trials Pty Ltd
- First posted
- Aug 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this intervention study is to assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Participants. The main parameters it aims to answer are: Does a single dose of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in healthy participants impact the Safety, Tolerability, Pharmacokinetics, and Immunogenicity profiles? This study will be a randomized, double blind, placebo-controlled study.
Conditions
- Psoriasis
Interventions
HCXT-2001 TabletsDrug
Two tablets taken orally in a fasted state
PlaceboDrug
Two tablets taken orally in a fasted state
HCXT-2001 Tablets(A)Drug
Two tablets taken orally in a fasted state
HCXT-2001 TabletsDrug
One tablet taken orally in a fasted state
PlaceboDrug
One tablet taken orally in a fasted state
HCXT-2001 Tablets(A)Drug
One tablet taken orally in a fasted state
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with AEs,SEAs, with abnormal - vital signs,physcial examinations,clinical laboratory results ,12-lead ECGs and stool routine testsTime frame: Day 1 to Day 50
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
New Zealand Clinical Research Christchurch
Christchurch, New Zealand
New Zealand Clinical Research Auckland
Grafton, New Zealand
Momentum Clinical Research (MCR)
Takapuna, Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.